In malaria-endemic countries, 350 million people are predicted to be deficient in an enzyme that means they can suffer severe complications from taking primaquine, a key drug for treating relapsing malaria, according to a study funded by the Wellcome Trust and published in this week's PLOS Medicine.
This finding is important as primaquine is recommended in the global action plan to eliminate malaria and is the only drug to prevent malaria relapse. The benefits of implementing a treatment program with this drug need to be weighed against the potential harm to a substantial proportion of the population (up to 8%) who may have G6PD deficiency: a genetic defect reducing glucose-6-phosphate dehydrogenase enzyme activitiy. Individuals with G6PD deficiency who are given primaquine can experience a severe complication – the breakdown of their red blood cells (hemolysis).
The authors from Indonesia, Kenya, the Philippines, and the United Kingdom, led by Rosalind Howes from the University of Oxford, reached these conclusions by inputting information about the frequency of G6PD deficiency from community surveys into a geostatistical model. Using the model, the authors predicted that G6PD deficiency is widespread across malaria-endemic regions, with the lowest frequencies in North and South America and the highest frequency in tropical Africa and the Arabian Peninsula.
Dr Howe explains: "Malaria control and elimination are a top priority on the global health agenda. Yet, a key drug to help achieve this goal remains too dangerous for widespread use. We have developed a map of this risk factor, G6PD deficiency, and find it to be very common across many malaria endemic regions. Much work remains to be done to fully understand this disease, notably its genetic diversity."
The authors found that the predicted frequency of G6PD deficiency varied considerably over relatively short distances in many areas but the overall frequency was 8% in malaria-endemic countries, corresponding to about 350 million affected individuals. In countries that are currently planning to implement malaria elimination programs, the frequency was 5.3%, corresponding to 100 million affected individuals.
When the authors took the severity of the G6PD deficiency (the more severe the deficiency, the higher the risk of hemolysis), they found that the greatest risk was across Asia, where severe G6PD variants are commonly inherited.
The authors say: The prominence of G6PD deficiency represents a barrier to current options for malaria elimination therapy."
They continue: "The complexity and diversity of both malaria epidemiology and G6PD deficiency mean that no single solution will be applicable for ensuring safe and effective primaquine treatment."
Public Library of Science: http://www.plos.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
For the first time, researchers have tracked the spread of Ebola, almost in real time, during an outbreak. The virus is quickly changing its DNA. But it's still unclear what these mutations mean.
Think of all the adults you know. Think of your parents and grandparents. Think of the teachers you had at school, your doctors and dentists, the people who collect your rubbish, and the actors you see on TV. All of these people probably have little mites crawling, eating, sleeping, and having sex on their faces.
A trial vaccine against Ebola could be tested on healthy volunteers in the UK in September, says an international health consortium.
The ALS Association has raised more than $94 million in recent weeks via its online ice bucket challenge — compared with $2.7 million this time last year. Now what?
Implant attached to bone in pioneering technique that helps prevent infection and discomfort
A new method for removing allergens from peanuts means help could soon be on the way for the roughly 2.8 million Americans with a potentially life-threatening allergy to the popular food, the U.S. Department of Agriculture said on Tuesday.
Survey finds many social media users hesitate to express opinions unless they know their followers will agree with them
Ebola has a nasty reputation for damaging the body, especially its blood vessels. But when you look at the nitty-gritty details of what happens after a person is infected, a surprising fact surfaces.
You think bringing a new toothbrush to market is easy? The seven-year saga of two dental entrepreneurs struggling to bring their patented brush to consumers suggests otherwise.
Scholars have long tried to understand how culture affects communities. New research argues that the parking behavior of drivers may tell us something about the economic productivity of nations.